Exploring the Potential Pharmacologic Mechanism of Heterophyllin B in the Treatment of Esophageal Cancer by Network Pharmacology

This study used the method of network pharmacology to preliminarily predict the mechanism of Heterophyllin B(HB) inhibiting Esophageal Cancer(EC). We found the HB targets in the TCMSP and PuChem databases, and searched all EC-related targets in the GeneCards database. Taken the intersection of HB an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:E3S Web of Conferences 2021, Vol.271, p.3036
Hauptverfasser: Chen, Ting, Zhang, Liang, Huang, Xulong, Chen, Haiyu, Zhu, Shengpeng, Huang, Chao, Huang, Bin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study used the method of network pharmacology to preliminarily predict the mechanism of Heterophyllin B(HB) inhibiting Esophageal Cancer(EC). We found the HB targets in the TCMSP and PuChem databases, and searched all EC-related targets in the GeneCards database. Taken the intersection of HB and EC as potential targets for inhibiting EC, and used Cytoscape 3.7.1 software to perform topological analysis on potential targets to obtain core targets. Used the start Analysisi function in the DAVID database to analyzed the biological process of the core target, and visualized it with the the R language tool. As a result, 75 potential targets for inhibiting EC were obtained, of which MMP9, MMP2, CCND1, STAT3, CXCR4, BDKRB1and PTGS2 were the main core targets. HB inhibits the occurrence of EC through Pathways in cancer, TNF signaling pathway, Bladder cancer, Small cell lung cancer, Rheumatoid arthritis related pathways, mainly involving proteolysis, collagen catabolic process, extracellular matrix disassembly, positive regulation of cell proliferation, positive regulation of cytosolic calcium ion concentration biological processes. This study initially revealed the molecular mechanism of HB inhibiting EC, and provided a reference for HB to expand new indications.
ISSN:2267-1242
2555-0403
2267-1242
DOI:10.1051/e3sconf/202127103036